inebilizumab  (Amgen)

Journal: Pharmaceutics

Article Title: Molecule Formats of B-Cell Targeting Biologics: Applications in Autoimmune Disease Treatment and Impacts on Manufacturability

doi: 10.3390/pharmaceutics17040495

Figure Lengend Snippet: B-cell targeted biologics in autoimmune diseases and their molecule formats and features.

Article Snippet: Developed by Viela Bio and acquired by Horizon Therapeutics and more recently by Amgen, inebilizumab is a humanized IgG1 mAb targeting the extracellular loop of CD19 [ , ], It initially received FDA approval in 2020 for the treatment of NMOSD in adult patients who are seropositive for immunoglobulin G (IgG) autoantibodies against aquaporin-4 (AQP4) [ ].

Techniques: Clinical Proteomics, Activity Assay, Activation Assay, Blocking Assay, Derivative Assay, Binding Assay

Journal: Pharmaceutics

Article Title: Molecule Formats of B-Cell Targeting Biologics: Applications in Autoimmune Disease Treatment and Impacts on Manufacturability

doi: 10.3390/pharmaceutics17040495

Figure Lengend Snippet: Trend in molecule formats of B-cell-targeting biologics launched or clinically trialed for autoimmune diseases. With a better understanding of the field and technological advancement, more diversified formats and enhanced features have been developed with time. Many molecules have been proven successful in oncology and are being introduced for autoimmune disease treatment [ , ]. Approximate timeline in the diagram is for the time when those biologics entered the clinical trials for autoimmune indications. ❶ = rituximab, SM03; ❷ = ublituximab; ❸ = veltuzumab, epratuzumab; BI 655064; ❹ = ocrelizumab, inebilizumab; ❺ = ofatumumab, daratumumab, belimumab, ianalumab; ❻ = iscalimab; ❼ = telitacicept, atacicept; ❽ = TRU-015; ❾ = dapirolizumab pegol; ❿ = dazodalibep; ⓫ = PRV-3279, mosunetuzumab, obexelimab, blinatumomab; ⓬ = imvotamab; ⓭ = PIT565.

Article Snippet: Developed by Viela Bio and acquired by Horizon Therapeutics and more recently by Amgen, inebilizumab is a humanized IgG1 mAb targeting the extracellular loop of CD19 [ , ], It initially received FDA approval in 2020 for the treatment of NMOSD in adult patients who are seropositive for immunoglobulin G (IgG) autoantibodies against aquaporin-4 (AQP4) [ ].

Techniques: Clinical Proteomics